Viruses are entirely dependent on their hosts to reproduce. They ransack living cells for parts and energy and hijack the host's cellular machinery to make new copies of themselves. Herpes simplex ...

Researchers at the University of Jyväskylä (Finland), in cooperation with national and international research groups, have ...

A common hallmark of viral genome replication is a high mutation rate, which can aid in their ability to evade new treatments and acquire resistance to once-effective antiviral medications. Now, a new ...

Three-phase treatment offers patients with HSV infections an alternative to perpetual antiviral management ROATAN, BAY ...

A phase 3 trial finds pritelivir significantly improves cure rates for immunocompromised individuals with refractory HSV infections.

A recent international research project has used advanced microscopy techniques and computational modeling to discover why ...

The trial enrolled and treated 101 immunocompromised patients with refractory or resistant HSV infection.

Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with ...

Current treatments for herpes simplex virus 1 (HSV-1) mainly target the viral DNA polymerase, but resistance is becoming an increasing problem. By understanding how HSV-1 initiates replication, ...

TORONTO, ON / ACCESSWIRE / September 3, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research ...